Evaluation and control of lung inflammation assessed with positron emission tomography (PET) scanning in emphysema

Completed

• Conditions: Chronic obstructive pulmonary disease (COPD), emphysema, alpha 1-antitrypsin deficiency; Respiratory; Emphysema

• Registration Number: ISRCTN80875207
• Lead Sponsor: niversity Hospitals Birmingham NHS Foundation Trust (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2008-10-31
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Healthy controls:
1. Healthy subjects
2. Both males and females, aged 50 - 70 years
3. Those who have never smoked regularly for more than 3 months
4. No evidence of lung disease
5. Forced expiratory volume in 1 second (FEV1) greater than 75% predicted, FEV1/forced vital capacity (FVC) greater than 70% predicted
6. No relevant medical or mental disorder
7. Able to give informed consent

COPD patients:
1. Emphysema with no other active lung disease
2. FEV1 less than 75% predicted, FEV1/FVC less than 70% predicted, carbon monoxide transfer coefficient (KCO) less than 80% predicted (or known emphysema on previous CT scan)
3. Fewer than two acute exacerbations in the previous 12 months and no recent exacerbations (within 2 months)
4. No other relvant medical or mental disorder
5. Able to give informed consent

Patients with alpha 1-antitrypsin deficiency:
1. PiZ phenotype
2. Emphysema with no other active lung disease
3. FEV1 less than 75% predicted, FEV1/FVC less than 70% predicted, KCO less than 80% predicted (or known emphysema on previous CT scan)
4. Fewer than two acute exacerbations in the previous 12 months and no recent exacerbations (within 2 months)
5. No other relvant medical or mental disorder
6. Able to give informed consent

Exclusion Criteria

Does not comply with the above inclusion criteria

Study & Design

• Study Type: Interventional
• Study Design: Not specified